TABLE 2.

In vivo data before and after treatment with sGC activator in control and DSS groups.

	Control	Control + sGC	DAHL	DAHL + sGC
IVRT (ms)	28.25 ± 0.1	28.32 ± 0.1	34.44 ± 0.7***	28.46 ± 0.4†⁣†⁣†
E/A	2.0 ± 0.1	2.0 ± 0.02	1.2 ± 0.02***	1.44 ± 0.03†⁣†⁣†
e′/a′	1.6 ± 0.1	1.8 ± 0.05	1.24 ± 0.04	1.34 ± 0.03
EF	55.11 ± 1.1	54.8 ± 0.1	56.14 ± 3.61	53.5 ± 1.2
dP/dtmax (mmHg/s)	8.610 ± 211.6	8.334 ± 55.5	9.772 ± 122.0*	8.538 ± 163.7†
dP/dtmin (mmHg/s)	−10.578 ± 138.6	−10.201 ± 185	−8.423.25 ± 180*	−10.203 ± 357†
Tau (ms)	9.94 ± 1.8	10.17 ± 0.1	11.55 ± 0.7	9.8 ± 0.21(p = 0.06)
TD (ms)	28.90 ± 1.2	27.30 ± 1.0	37.70 ± 1.0**	26.95 ± 0.96†⁣†

LV, left ventricular; IVRT, isovolumetric relaxation time; A, peak trans-mitral late left LV diastolic filling velocity; E, peak trans-mitral early LV diastolic filling velocity; a’, peak late diastolic mitral annular velocity by tissue Doppler; e’, peak early diastolic mitral annular velocity by tissue Doppler; EF, ejection fraction; dP/dtmax, the maximal slope of LV systolic pressure increment; dP/dtmin, the maximal slope of LV diastolic pressure decrement; Tau (τ), the time constant for isovolumic relaxation; DT, E wave deceleration time; sGC, soluble guanylyl cyclase. Data are shown as mean ± SEM; *P < 0.05, ^∗∗P < 0.001,*^∗∗P < 0.0001 control untreated versus DSS untreated and ^†P < 0.05, ^†⁣†P < 0.001, ^{†⁣†⁣†}P < 0.0001 before versus after sGC activator treatment.